Eli Lilly and Company (LLY) 86.14 $LLY
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
at The Street - 1 hr 5 mins ago
It's government shutdown season and that's never good for the stock market, Cramer says. So he'll be watching Washington as well as earnings from Johnson & Johnson and Wells Fargo.
GE: 28.07 (+0.04), HON: 101.16 (+0.09), DAL: 47.21 (+1.25), C: 51.38 (-0.27), PSTG: 16.60 (+0.67), QSII: 12.54 (+0.11), INTC: 32.14 (-0.38), SLB: 76.36 (-0.28), JNJ: 95.37 (+0.29), T: 33.14 (-0.26), ETP: 46.39 (+0.91), JPM: 61.93 (-0.20), GWPH: 87.75 (+0.45), HSIC: 141.70 (+0.51), GLNG: 32.01 (-1.47), LNG: 53.04 (-0.25), WFC: 52.14 (-0.40), BAC: 15.58 (-0.17), LLY: 86.14 (+2.37), BMY: 61.44 (+0.93), CSX: 29.08 (-0.01), CI: 136.36 (+2.73), RDUS: 57.80 (-3.30), WBA: 85.37 (+1.09), GS: 179.19 (-1.88), VZ: 44.16 (-0.07)
Eli Lilly's Breast Cancer Drug Gets Breakthrough Status
Zacks Equity Research - Zacks Investment Research - Fri Oct 09, 3:35PM CDT
Eli Lilly (LLY) received Breakthrough Therapy designation from the FDA for abemaciclib, being developed for the treatment of advanced breast cancer.
PFE: 33.24 (+0.15), AZN: 32.23 (-0.16), APRI: 1.65 (+0.03), LLY: 86.14 (+2.37)
World Mental Health Day: De-Stress with 4 Stocks
Zacks Equity Research - Zacks Investment Research - Fri Oct 09, 2:44PM CDT
The afflictions of the mind are heightened by the stress of modern living. However, when it comes to stock-picking, don't feel stressed -- leave it to us.
AGN: 274.84 (-1.32), GWPH: 87.75 (+0.45), LLY: 86.14 (+2.37), ALKS: 60.82 (+0.92)
Eli Lilly (LLY) Stock Climbs Following Analyst Upgrade
at The Street - Fri Oct 09, 9:11AM CDT
Eli Lilly (LLY) shares are rising after the company's stock was upgraded to 'outperform' from 'neutral' by analysts at Credit Suisse.
LLY: 86.14 (+2.37)
This Double-Whammy Sent Merck Shares Notably Lower in September
Sean Williams, The Motley Fool - Motley Fool - Fri Oct 09, 9:03AM CDT
MRK data by YCharts . Shares of Big Pharma Merck struggled mightily in September, ending the month lower by 7.5% according to data from S&P Capital IQ . Since August 19, Merck's stock has dropped by almost 17%, wiping out more than $27...
MRK: 50.95 (-0.07), LLY: 86.14 (+2.37)
Analysts' Actions -- Eli Lilly, Tesla, Wells Fargo, Gap
at The Street - Fri Oct 09, 7:48AM CDT
Here are Friday's top research calls, including upgrades at Eli Lilly and Wells Fargo, downgrades at Gap and Tesla.
ASH: 105.52 (-2.20), NFLX: 113.33 (-1.60), TSLA: 220.69 (-6.03), RIG: 16.98 (+0.68), GPN: 133.02 (+0.57), ALB: 50.72 (+0.15), LLY: 86.14 (+2.37), WFC: 52.14 (-0.40), GPS: 27.42 (-1.53), BEN: 38.85 (-0.04), ECL: 120.54 (+0.01)
Global & USA Cancer Immunotherapy Market Analysis 2015 - Forecasts to 2020
PR Newswire Europe - Fri Oct 09, 7:10AM CDT
Research and Markets(http://www.researchandmarkets.com/research/lgcqzq/global_and_usa [http://www.researchandmarkets.com/research/lgcqzq/global_and_usa]) has announced the addition of the "Global & USA Cancer Immunotherapy Market Analysis to 2020" [http://www.researchandmarkets.com/research/lgcqzq/global_and_usa] report to their offering.
HTBX: 4.25 (+0.03), BIIB: 269.16 (-10.72), NWBO: 6.16 (-0.08), CVM: 0.72 (-0.02), CLDX: 12.80 (+1.06), MACK: 9.60 (+0.17), INO: 6.16 (+0.20), NLNK: 34.31 (+1.42), JUNO: 48.64 (+0.84), GALE: 1.74 (+0.01), IMMU: 2.17 (+0.12), ADXS: 11.07 (+0.83), ADRO: 22.06 (+0.32), IMGN: 10.91 (+0.25), AMGN: 149.59 (-0.31), SPPI: 6.20 (+0.07), LLY: 86.14 (+2.37), BMY: 61.44 (+0.93), GSK: 40.22 (+0.06), SRNE: 8.61 (+0.05), ONTY: 2.88 (+0.08), IMUC: 0.44 (-0.01), PGNX: 5.77 (+0.26), ARGS: 5.79 (-0.19), GBIM: 2.54 (+0.02), BLCM: 14.65 (+0.39), SGEN: 39.38 (+0.87), KITE: 63.33 (+0.26), MRK: 50.95 (-0.07)
Eli Lilly and Company Expands New York City Research and Development Site
PR Newswire - Fri Oct 09, 6:00AM CDT
Eli Lilly and Company (NYSE: LLY) today announced plans to add 30,000 square feet and approximately 50 new jobs to its research and development presence at the Alexandria Center for Life Science in New York, New York.
ARE: 89.94 (-0.79), LLY: 86.14 (+2.37)
Eli Lilly (LLY) Breaks Through Support at $82.64
Comtex SmarTrend(R) - Thu Oct 08, 10:51AM CDT
Shares of Eli Lilly (NYSE:LLY) opened today below their pivot of $83.75 and have already reached the first level of support at $82.64. Should the shares continue to fall, the support pivots of $81.30 and $78.85 will be of interest.
LLY: 86.14 (+2.37)
Research and Markets: Global Diabetes Market Report: 2015 Edition Featuring Eli Lilly, Novo Nordisk, Sanofi & Takeda
Business Wire - Thu Oct 08, 9:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qw634x/global_diabetes) has announced the addition of the "Global Diabetes Market Report: 2015 Edition" report to their offering.
NVO: 54.61 (-0.12), LLY: 86.14 (+2.37)
Global Diabetes Market Report: 2015 Edition Featuring Eli Lilly, Novo Nordisk, Sanofi & Takeda
M2 - Thu Oct 08, 9:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5rlln5/global_diabetes) has announced the addition of the "Global Diabetes Market Report: 2015 Edition" report to their offering. The report Global Diabetes Market provides an in-depth analysis of the global diabetes market, along with an in-depth study of the regional markets. The major trends, growth drivers as well as issues being faced by the industry are being presented in this report. The major players in the industry, Novo-Nordisk, Sanofi-Aventis, Eli Lilly and Takeda are being profiled. The key factors driving the growth of the diabetes market are growing evidence of insulin therapy, rising healthcare expenditure, rising obese population, increasing urbanization and ageing population. Some of the noteworthy trends and developments of this industry are increasing prevalence of diabetes, rising diabetes cases due to second hand smoke, and rise of impaired glucose tolerance (IGT). However, the expansion of global diabetes market is hindered by increasing treatment cost and lack of sufficient diagnosis and treatment facilities. Key Topics Covered: 1. Introduction to Diabetes 2. Global Diabetes Market 3. Regional Analysis 4. Market Dynamics 5. Competitive Landscape 6. Company Profiles 7. Market Outlook Companies Mentioned - Eli Lilly - Novo Nordisk - Sanofi - Takeda For more information visit http://www.researchandmarkets.com/research/5r...l_diabetes
NVO: 54.61 (-0.12), LLY: 86.14 (+2.37)
Global Animal Health Market Report: 2015 Edition
M2 - Thu Oct 08, 9:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7vrc8c/global_animal) has announced the addition of the "Global Animal Health Market Report: 2015 Edition" report to their offering. The report, Global Animal Health Market analyzes the development of the animal health market, with a focus on its segments including: market for companion animals and food producing animals. The global market along with markets of the U.S., Europe and India are being discussed in the report. Animals like humans also suffer from diseases and hence require proper care from veterinarians, farmers and pet owners. Improving the health and well-being of companion animals, livestock and wild animals and treating them is the foremost objective of animal health industry. Companion animals are the animals that are kept by people for companionship, protection and enjoyment whereas food producing animals are those which are raised in agricultural setting to produce commodities such as food and fiber and thereby serve the purpose of feeding humans. Animal health products, also known as veterinary medicines are pharmaceuticals, vaccines and feed additives used to keep animals healthy. These medicines help companion animals live longer and healthier lives and increase productivity of livestock. Increasing animal meat consumption globally, rising ageing population, improving economic conditions with rise in the global GDP, increasing urban population, faster and cheaper regulatory approvals, increasing scope for Biologics and Oncolytic and improving drought conditions in high plain regions of the U.S., are the major factors contributing to the growth of animal health market. However, the growth of the market has been hindered by certain challenges including major threats from new entrants and generic companies, entrance of other players in food retail space and increased cost of product development. The major trends, growth drivers as well as issues being faced by the industry are being presented in this report. The three major players in the industry - Zoetis, Merck, Elli Lilly and Sanofi are being profiled, along with their key financials and strategies for growth. Key Topics Covered: 1. Market Overview 2. Market Analysis 3. Regional Markets 4. Market Dynamics 5. Competitive Landscape 6. Company Profiles 7. Market Outlook Companies Mentioned - Eli Lilly and Company - Merck and Co - Sanofi - Zoetis Inc. For more information visit http://www.researchandmarkets.com/research/7v...bal_animal
ZTS: 42.80 (-0.42), MRK: 50.95 (-0.07), LLY: 86.14 (+2.37)
Lilly Receives FDA Breakthrough Therapy Designation for Abemaciclib - a CDK 4 and 6 Inhibitor - in Advanced Breast Cancer
PR Newswire - Thu Oct 08, 6:00AM CDT
Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to abemaciclib, a cyclin-dependent kinase (CDK) 4 and 6 inhibitor, for patients with refractory hormone-receptor-positive (HR+) advanced or metastatic breast cancer. This designation is based on data from the breast cancer cohort expansion of the company's Phase I trial, JPBA, which studied the efficacy and safety of abemaciclib in women with advanced or metastatic breast cancer. Patients in this cohort had received a median of seven prior systemic treatments. These data were presented at the San Antonio Breast Cancer Symposium in 2014.
LLY: 86.14 (+2.37)
Mallinckrodt (MNK) Issues Fiscal 2016 Guidance, Shares Up
Zacks Equity Research - Zacks Investment Research - Wed Oct 07, 3:25PM CDT
Mallinckrodt (MNK) was up 2.6% after the company provided the fiscal 2016 outlook.
MNK: 66.73 (-1.81), AZN: 32.23 (-0.16), TEVA: 58.96 (-0.28), LLY: 86.14 (+2.37)
Lilly Confirms Date and Conference Call for Third-Quarter 2015 Financial Results Announcement
PR Newswire - Wed Oct 07, 12:00PM CDT
Eli Lilly and Company (NYSE: LLY) will announce its financial results for the third quarter of 2015 on Thursday, October 22, 2015. Lilly will also conduct a conference call on that day with the investment community and media to further detail the company's financial performance.
LLY: 86.14 (+2.37)
Jim Cramer -- Microsoft, General Mills, WhiteWave Are Buying Opportunities
at The Street - Wed Oct 07, 11:59AM CDT
Jim Cramer answers viewers questions from social media on the floor of the New York Stock Exchange.
BLUE: 88.80 (+0.30), BIIB: 269.16 (-10.72), FB: 93.24 (+0.77), XOM: 79.26 (-0.77), AMGN: 149.59 (-0.31), LLY: 86.14 (+2.37), BMY: 61.44 (+0.93), INTC: 32.14 (-0.38), CELG: 117.38 (-0.59), WWAV: 43.82 (+2.11), MSFT: 47.11 (-0.34), TWTR: 30.85 (+0.53), CVX: 89.57 (-0.34), GIS: 56.61 (+0.13)
The Zacks Analyst Blog Highlights: CVS Health, Amgen, Eli Lilly, AbbVie and Teva Pharmaceutical
Zacks Equity Research - Zacks Investment Research - Wed Oct 07, 8:30AM CDT
The Zacks Analyst Blog Highlights: CVS Health, Amgen, Eli Lilly, AbbVie and Teva Pharmaceutical
AMGN: 149.59 (-0.31), CVS: 102.00 (-0.17), TEVA: 58.96 (-0.28), ABBV: 55.64 (-0.40), LLY: 86.14 (+2.37)
Lilly Joins the Imaging Dementia - Evidence for Amyloid Scanning (IDEAS) Study
PR Newswire - Wed Oct 07, 7:00AM CDT
Eli Lilly and Company (NYSE:LLY) and Avid Radiopharmaceuticals, Inc., a wholly owned subsidiary of Lilly, today announced financial commitment and continued scientific partnership to support the recently established Imaging Dementia - Evidence for Amyloid Scanning (IDEAS) Study.
LLY: 86.14 (+2.37)
Global Diabetes Care Devices Market Outlook 2015-2020 - Market is Expected to Grow at a CAGR of 5.2%
M2 - Wed Oct 07, 6:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jb8dxs/global_diabetes) has announced the addition of the "Global Diabetes Care Devices Market Outlook: 2015-2020" report to their offering. The global diabetes care devices market is expected to grow at a CAGR of 5.2% from 2015 to 2020 to reach $24.6 billion by 2020 This market is mainly driven by increasing prevalence of diabetes, technological advancements, rise in obese population, sedentary lifestyle and improper diet, and increasing need for faster and safer diagnosis and treatment of diabetes. Furthermore, huge investments by the market leaders and foraying of new companies into this market, wide scope of penetration in untapped and emerging markets, and rising awareness among people about diabetes care are also accelerating the growth of this market. However, high cost associated with diagnosis and treatment, reimbursement issues for new technologies, lack of awareness, strict regulatory obligations, and high cost of diabetic food hinders the growth of this market to some extent. The research report on the diabetes care devices market provides comprehensive analysis of the global market with a country level analysis and helps in understanding the driving forces for the growth of this market. The report also provides analysis of major product segments such as diabetes control solutions, diabetes monitoring devices, and insulin delivery devices. The diabetes monitoring devices segment further sub-segmented into continuous blood glucose monitoring devices, test strips, lancets, and hemoglobin A1c (HbA1c) testing kits. The insulin delivery devices further sub-segmented into insulin syringes, insulin pens, insulin pumps, and insulin injectors. Key Topics Covered: 1 Introduction to Diabetes Care Devices Market 2 Executive Summary 3 Market Insights 4 Global Diabetes Care Devices- Market Crackdown ($ Value Analysis), By Product Type 5 Diabetes Care Devices- Market Crackdown ($ Value Analysis), By Geography 6 Global Diabetes Care Devices Market- Competitive Landscape 7 Company Profiles - ARKRAY Inc. - Abbott Laboratories - Bayer HealthCare AG - Becton, Dickinson and Company - Dexcom, Inc. - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - Johnson & Johnson - Medtronic, Inc. - Novo Nordisk A/S - Sanofi S.A - Tandem Diabetes Care, Inc - Terumo Corporation - Ypsomed AG For more information visit http://www.researchandmarkets.com/research/jb...l_diabetes
JNJ: 95.37 (+0.29), ABT: 41.89 (+0.73), NVO: 54.61 (-0.12), MDT: 72.60 (+0.55), LLY: 86.14 (+2.37)
Global Mild Cognitive Impairment Pipeline Review H2 2015 - 11 Companies & 21 Drug Profiles
M2 - Wed Oct 07, 3:12AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2nrq57/mild_cognitive) has announced the addition of the "Mild Cognitive Impairment - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Mild cognitive impairment, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mild cognitive impairment and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Actinogen Limited - Avraham Pharmaceuticals Ltd. - Boehringer Ingelheim GmbH - CereSpir Incorporated - D-Pharm Ltd. - Eisai Co., Ltd. - Eli Lilly and Company - Octapharma AG - Sage Therapeutics - Sanofi - Suven Life Sciences Ltd. Drug Profiles - BAN-2401 - BCA-909 - CSP-1103 - DAOI-B - DP-NDD - immune globulin (human) - insulin (human) - ladostigil tartrate - levetiracetam - LY-3002813 - SAGE-547 - SAR-228810 - Small Molecule to Antagonize nAChR Alpha-4 Beta-2 for CNS Disorders - SUVN-501 - SUVN-502 - SUVN-507 - SUVN-512 - SUVN-976 - SUVND-4010 - tropisetron hydrochloride - UE-2343 For more information visit http://www.researchandmarkets.com/research/2n..._cognitive
LLY: 86.14 (+2.37)
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
at The Street - 1 hr 5 mins ago
It's government shutdown season and that's never good for the stock market, Cramer says. So he'll be watching Washington as well as earnings from Johnson & Johnson and Wells Fargo.
GE: 28.07 (+0.04), HON: 101.16 (+0.09), DAL: 47.21 (+1.25), C: 51.38 (-0.27), PSTG: 16.60 (+0.67), QSII: 12.54 (+0.11), INTC: 32.14 (-0.38), SLB: 76.36 (-0.28), JNJ: 95.37 (+0.29), T: 33.14 (-0.26), ETP: 46.39 (+0.91), JPM: 61.93 (-0.20), GWPH: 87.75 (+0.45), HSIC: 141.70 (+0.51), GLNG: 32.01 (-1.47), LNG: 53.04 (-0.25), WFC: 52.14 (-0.40), BAC: 15.58 (-0.17), LLY: 86.14 (+2.37), BMY: 61.44 (+0.93), CSX: 29.08 (-0.01), CI: 136.36 (+2.73), RDUS: 57.80 (-3.30), WBA: 85.37 (+1.09), GS: 179.19 (-1.88), VZ: 44.16 (-0.07)
Eli Lilly's Breast Cancer Drug Gets Breakthrough Status
Zacks Equity Research - Zacks Investment Research - Fri Oct 09, 3:35PM CDT
Eli Lilly (LLY) received Breakthrough Therapy designation from the FDA for abemaciclib, being developed for the treatment of advanced breast cancer.
PFE: 33.24 (+0.15), AZN: 32.23 (-0.16), APRI: 1.65 (+0.03), LLY: 86.14 (+2.37)
World Mental Health Day: De-Stress with 4 Stocks
Zacks Equity Research - Zacks Investment Research - Fri Oct 09, 2:44PM CDT
The afflictions of the mind are heightened by the stress of modern living. However, when it comes to stock-picking, don't feel stressed -- leave it to us.
AGN: 274.84 (-1.32), GWPH: 87.75 (+0.45), LLY: 86.14 (+2.37), ALKS: 60.82 (+0.92)
Eli Lilly (LLY) Stock Climbs Following Analyst Upgrade
at The Street - Fri Oct 09, 9:11AM CDT
Eli Lilly (LLY) shares are rising after the company's stock was upgraded to 'outperform' from 'neutral' by analysts at Credit Suisse.
LLY: 86.14 (+2.37)
This Double-Whammy Sent Merck Shares Notably Lower in September
Sean Williams, The Motley Fool - Motley Fool - Fri Oct 09, 9:03AM CDT
MRK data by YCharts . Shares of Big Pharma Merck struggled mightily in September, ending the month lower by 7.5% according to data from S&P Capital IQ . Since August 19, Merck's stock has dropped by almost 17%, wiping out more than $27...
MRK: 50.95 (-0.07), LLY: 86.14 (+2.37)
Analysts' Actions -- Eli Lilly, Tesla, Wells Fargo, Gap
at The Street - Fri Oct 09, 7:48AM CDT
Here are Friday's top research calls, including upgrades at Eli Lilly and Wells Fargo, downgrades at Gap and Tesla.
ASH: 105.52 (-2.20), NFLX: 113.33 (-1.60), TSLA: 220.69 (-6.03), RIG: 16.98 (+0.68), GPN: 133.02 (+0.57), ALB: 50.72 (+0.15), LLY: 86.14 (+2.37), WFC: 52.14 (-0.40), GPS: 27.42 (-1.53), BEN: 38.85 (-0.04), ECL: 120.54 (+0.01)
Global & USA Cancer Immunotherapy Market Analysis 2015 - Forecasts to 2020
PR Newswire Europe - Fri Oct 09, 7:10AM CDT
Research and Markets(http://www.researchandmarkets.com/research/lgcqzq/global_and_usa [http://www.researchandmarkets.com/research/lgcqzq/global_and_usa]) has announced the addition of the "Global & USA Cancer Immunotherapy Market Analysis to 2020" [http://www.researchandmarkets.com/research/lgcqzq/global_and_usa] report to their offering.
HTBX: 4.25 (+0.03), BIIB: 269.16 (-10.72), NWBO: 6.16 (-0.08), CVM: 0.72 (-0.02), CLDX: 12.80 (+1.06), MACK: 9.60 (+0.17), INO: 6.16 (+0.20), NLNK: 34.31 (+1.42), JUNO: 48.64 (+0.84), GALE: 1.74 (+0.01), IMMU: 2.17 (+0.12), ADXS: 11.07 (+0.83), ADRO: 22.06 (+0.32), IMGN: 10.91 (+0.25), AMGN: 149.59 (-0.31), SPPI: 6.20 (+0.07), LLY: 86.14 (+2.37), BMY: 61.44 (+0.93), GSK: 40.22 (+0.06), SRNE: 8.61 (+0.05), ONTY: 2.88 (+0.08), IMUC: 0.44 (-0.01), PGNX: 5.77 (+0.26), ARGS: 5.79 (-0.19), GBIM: 2.54 (+0.02), BLCM: 14.65 (+0.39), SGEN: 39.38 (+0.87), KITE: 63.33 (+0.26), MRK: 50.95 (-0.07)
Eli Lilly and Company Expands New York City Research and Development Site
PR Newswire - Fri Oct 09, 6:00AM CDT
Eli Lilly and Company (NYSE: LLY) today announced plans to add 30,000 square feet and approximately 50 new jobs to its research and development presence at the Alexandria Center for Life Science in New York, New York.
ARE: 89.94 (-0.79), LLY: 86.14 (+2.37)
Eli Lilly (LLY) Breaks Through Support at $82.64
Comtex SmarTrend(R) - Thu Oct 08, 10:51AM CDT
Shares of Eli Lilly (NYSE:LLY) opened today below their pivot of $83.75 and have already reached the first level of support at $82.64. Should the shares continue to fall, the support pivots of $81.30 and $78.85 will be of interest.
LLY: 86.14 (+2.37)
Research and Markets: Global Diabetes Market Report: 2015 Edition Featuring Eli Lilly, Novo Nordisk, Sanofi & Takeda
Business Wire - Thu Oct 08, 9:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qw634x/global_diabetes) has announced the addition of the "Global Diabetes Market Report: 2015 Edition" report to their offering.
NVO: 54.61 (-0.12), LLY: 86.14 (+2.37)
Global Diabetes Market Report: 2015 Edition Featuring Eli Lilly, Novo Nordisk, Sanofi & Takeda
M2 - Thu Oct 08, 9:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5rlln5/global_diabetes) has announced the addition of the "Global Diabetes Market Report: 2015 Edition" report to their offering. The report Global Diabetes Market provides an in-depth analysis of the global diabetes market, along with an in-depth study of the regional markets. The major trends, growth drivers as well as issues being faced by the industry are being presented in this report. The major players in the industry, Novo-Nordisk, Sanofi-Aventis, Eli Lilly and Takeda are being profiled. The key factors driving the growth of the diabetes market are growing evidence of insulin therapy, rising healthcare expenditure, rising obese population, increasing urbanization and ageing population. Some of the noteworthy trends and developments of this industry are increasing prevalence of diabetes, rising diabetes cases due to second hand smoke, and rise of impaired glucose tolerance (IGT). However, the expansion of global diabetes market is hindered by increasing treatment cost and lack of sufficient diagnosis and treatment facilities. Key Topics Covered: 1. Introduction to Diabetes 2. Global Diabetes Market 3. Regional Analysis 4. Market Dynamics 5. Competitive Landscape 6. Company Profiles 7. Market Outlook Companies Mentioned - Eli Lilly - Novo Nordisk - Sanofi - Takeda For more information visit http://www.researchandmarkets.com/research/5r...l_diabetes
NVO: 54.61 (-0.12), LLY: 86.14 (+2.37)
Global Animal Health Market Report: 2015 Edition
M2 - Thu Oct 08, 9:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7vrc8c/global_animal) has announced the addition of the "Global Animal Health Market Report: 2015 Edition" report to their offering. The report, Global Animal Health Market analyzes the development of the animal health market, with a focus on its segments including: market for companion animals and food producing animals. The global market along with markets of the U.S., Europe and India are being discussed in the report. Animals like humans also suffer from diseases and hence require proper care from veterinarians, farmers and pet owners. Improving the health and well-being of companion animals, livestock and wild animals and treating them is the foremost objective of animal health industry. Companion animals are the animals that are kept by people for companionship, protection and enjoyment whereas food producing animals are those which are raised in agricultural setting to produce commodities such as food and fiber and thereby serve the purpose of feeding humans. Animal health products, also known as veterinary medicines are pharmaceuticals, vaccines and feed additives used to keep animals healthy. These medicines help companion animals live longer and healthier lives and increase productivity of livestock. Increasing animal meat consumption globally, rising ageing population, improving economic conditions with rise in the global GDP, increasing urban population, faster and cheaper regulatory approvals, increasing scope for Biologics and Oncolytic and improving drought conditions in high plain regions of the U.S., are the major factors contributing to the growth of animal health market. However, the growth of the market has been hindered by certain challenges including major threats from new entrants and generic companies, entrance of other players in food retail space and increased cost of product development. The major trends, growth drivers as well as issues being faced by the industry are being presented in this report. The three major players in the industry - Zoetis, Merck, Elli Lilly and Sanofi are being profiled, along with their key financials and strategies for growth. Key Topics Covered: 1. Market Overview 2. Market Analysis 3. Regional Markets 4. Market Dynamics 5. Competitive Landscape 6. Company Profiles 7. Market Outlook Companies Mentioned - Eli Lilly and Company - Merck and Co - Sanofi - Zoetis Inc. For more information visit http://www.researchandmarkets.com/research/7v...bal_animal
ZTS: 42.80 (-0.42), MRK: 50.95 (-0.07), LLY: 86.14 (+2.37)
Lilly Receives FDA Breakthrough Therapy Designation for Abemaciclib - a CDK 4 and 6 Inhibitor - in Advanced Breast Cancer
PR Newswire - Thu Oct 08, 6:00AM CDT
Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to abemaciclib, a cyclin-dependent kinase (CDK) 4 and 6 inhibitor, for patients with refractory hormone-receptor-positive (HR+) advanced or metastatic breast cancer. This designation is based on data from the breast cancer cohort expansion of the company's Phase I trial, JPBA, which studied the efficacy and safety of abemaciclib in women with advanced or metastatic breast cancer. Patients in this cohort had received a median of seven prior systemic treatments. These data were presented at the San Antonio Breast Cancer Symposium in 2014.
LLY: 86.14 (+2.37)
Mallinckrodt (MNK) Issues Fiscal 2016 Guidance, Shares Up
Zacks Equity Research - Zacks Investment Research - Wed Oct 07, 3:25PM CDT
Mallinckrodt (MNK) was up 2.6% after the company provided the fiscal 2016 outlook.
MNK: 66.73 (-1.81), AZN: 32.23 (-0.16), TEVA: 58.96 (-0.28), LLY: 86.14 (+2.37)
Lilly Confirms Date and Conference Call for Third-Quarter 2015 Financial Results Announcement
PR Newswire - Wed Oct 07, 12:00PM CDT
Eli Lilly and Company (NYSE: LLY) will announce its financial results for the third quarter of 2015 on Thursday, October 22, 2015. Lilly will also conduct a conference call on that day with the investment community and media to further detail the company's financial performance.
LLY: 86.14 (+2.37)
Jim Cramer -- Microsoft, General Mills, WhiteWave Are Buying Opportunities
at The Street - Wed Oct 07, 11:59AM CDT
Jim Cramer answers viewers questions from social media on the floor of the New York Stock Exchange.
BLUE: 88.80 (+0.30), BIIB: 269.16 (-10.72), FB: 93.24 (+0.77), XOM: 79.26 (-0.77), AMGN: 149.59 (-0.31), LLY: 86.14 (+2.37), BMY: 61.44 (+0.93), INTC: 32.14 (-0.38), CELG: 117.38 (-0.59), WWAV: 43.82 (+2.11), MSFT: 47.11 (-0.34), TWTR: 30.85 (+0.53), CVX: 89.57 (-0.34), GIS: 56.61 (+0.13)
The Zacks Analyst Blog Highlights: CVS Health, Amgen, Eli Lilly, AbbVie and Teva Pharmaceutical
Zacks Equity Research - Zacks Investment Research - Wed Oct 07, 8:30AM CDT
The Zacks Analyst Blog Highlights: CVS Health, Amgen, Eli Lilly, AbbVie and Teva Pharmaceutical
AMGN: 149.59 (-0.31), CVS: 102.00 (-0.17), TEVA: 58.96 (-0.28), ABBV: 55.64 (-0.40), LLY: 86.14 (+2.37)
Lilly Joins the Imaging Dementia - Evidence for Amyloid Scanning (IDEAS) Study
PR Newswire - Wed Oct 07, 7:00AM CDT
Eli Lilly and Company (NYSE:LLY) and Avid Radiopharmaceuticals, Inc., a wholly owned subsidiary of Lilly, today announced financial commitment and continued scientific partnership to support the recently established Imaging Dementia - Evidence for Amyloid Scanning (IDEAS) Study.
LLY: 86.14 (+2.37)
Global Diabetes Care Devices Market Outlook 2015-2020 - Market is Expected to Grow at a CAGR of 5.2%
M2 - Wed Oct 07, 6:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jb8dxs/global_diabetes) has announced the addition of the "Global Diabetes Care Devices Market Outlook: 2015-2020" report to their offering. The global diabetes care devices market is expected to grow at a CAGR of 5.2% from 2015 to 2020 to reach $24.6 billion by 2020 This market is mainly driven by increasing prevalence of diabetes, technological advancements, rise in obese population, sedentary lifestyle and improper diet, and increasing need for faster and safer diagnosis and treatment of diabetes. Furthermore, huge investments by the market leaders and foraying of new companies into this market, wide scope of penetration in untapped and emerging markets, and rising awareness among people about diabetes care are also accelerating the growth of this market. However, high cost associated with diagnosis and treatment, reimbursement issues for new technologies, lack of awareness, strict regulatory obligations, and high cost of diabetic food hinders the growth of this market to some extent. The research report on the diabetes care devices market provides comprehensive analysis of the global market with a country level analysis and helps in understanding the driving forces for the growth of this market. The report also provides analysis of major product segments such as diabetes control solutions, diabetes monitoring devices, and insulin delivery devices. The diabetes monitoring devices segment further sub-segmented into continuous blood glucose monitoring devices, test strips, lancets, and hemoglobin A1c (HbA1c) testing kits. The insulin delivery devices further sub-segmented into insulin syringes, insulin pens, insulin pumps, and insulin injectors. Key Topics Covered: 1 Introduction to Diabetes Care Devices Market 2 Executive Summary 3 Market Insights 4 Global Diabetes Care Devices- Market Crackdown ($ Value Analysis), By Product Type 5 Diabetes Care Devices- Market Crackdown ($ Value Analysis), By Geography 6 Global Diabetes Care Devices Market- Competitive Landscape 7 Company Profiles - ARKRAY Inc. - Abbott Laboratories - Bayer HealthCare AG - Becton, Dickinson and Company - Dexcom, Inc. - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - Johnson & Johnson - Medtronic, Inc. - Novo Nordisk A/S - Sanofi S.A - Tandem Diabetes Care, Inc - Terumo Corporation - Ypsomed AG For more information visit http://www.researchandmarkets.com/research/jb...l_diabetes
JNJ: 95.37 (+0.29), ABT: 41.89 (+0.73), NVO: 54.61 (-0.12), MDT: 72.60 (+0.55), LLY: 86.14 (+2.37)
Global Mild Cognitive Impairment Pipeline Review H2 2015 - 11 Companies & 21 Drug Profiles
M2 - Wed Oct 07, 3:12AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2nrq57/mild_cognitive) has announced the addition of the "Mild Cognitive Impairment - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Mild cognitive impairment, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mild cognitive impairment and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Actinogen Limited - Avraham Pharmaceuticals Ltd. - Boehringer Ingelheim GmbH - CereSpir Incorporated - D-Pharm Ltd. - Eisai Co., Ltd. - Eli Lilly and Company - Octapharma AG - Sage Therapeutics - Sanofi - Suven Life Sciences Ltd. Drug Profiles - BAN-2401 - BCA-909 - CSP-1103 - DAOI-B - DP-NDD - immune globulin (human) - insulin (human) - ladostigil tartrate - levetiracetam - LY-3002813 - SAGE-547 - SAR-228810 - Small Molecule to Antagonize nAChR Alpha-4 Beta-2 for CNS Disorders - SUVN-501 - SUVN-502 - SUVN-507 - SUVN-512 - SUVN-976 - SUVND-4010 - tropisetron hydrochloride - UE-2343 For more information visit http://www.researchandmarkets.com/research/2n..._cognitive
LLY: 86.14 (+2.37)
